A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Clinical trial NCT06945705 · RECRUITING
Trial details
- NCT number
- NCT06945705
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-02
- Primary completion
- 2027-09-02
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.